Trimebutine

Trimebutine
Clinical data
Trade names	Debridat, Recutin, Polybutin, others
AHFS/Drugs.com	International Drug Names
ATC code	A03AA05 (WHO) ;
Physiological data
Agonists	opioid receptors
Antagonists	mAChR, sodium channels
Pharmacokinetic data
Metabolites	nortrimebutine, N-didesmethyltrimebutine, 2-dimethylamino-2-phenylbutan-1-ol, 2-methylamino-2-phenylbutan-1-ol, 2-amino-2-phenylbutan-1-ol
Elimination half-life	2.77 h (for oral dose 200 mg)
Excretion	renal, fecal
Identifiers
	IUPAC name 2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate;
CAS Number	39133-31-8 ;
PubChem CID	5573;
PubChem SID	310265016;
ChemSpider	5372 ;
UNII	QZ1OJ92E5R;
ChEBI	CHEBI:94458;
ChEMBL	ChEMBL190044 ;
CompTox Dashboard (EPA)	DTXSID4023707 ;
ECHA InfoCard	100.049.354
Chemical and physical data
Formula	C22H29NO5
Molar mass	387.476 g·mol−1
3D model (JSmol)	Interactive image;
Density	1.1±0.1 g/cm³ g/cm3
Boiling point	457.9 °C (856.2 °F) at 760 mmHg
	SMILES CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;
	InChI InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3 ; Key:LORDFXWUHHSAQU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Trimebutine is a drug with antimuscarinic and very weak mu opioid agonist effects.^[1] It is used for the treatment of irritable bowel syndrome and other gastrointestinal disorders. It is sometimes combined with simethicone as a combination drug.^[2] Trimebutine is formulated as a tablet or granules for oral suspension.^[3]

^ Kaneto H, Takahashi M, Watanabe J (July 1990). "The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies". Journal of Pharmacobio-dynamics. 13 (7): 448–453. doi:10.1248/bpb1978.13.448. hdl:10069/38849. PMID 1963196.
^ "Libertrim SII". Medicamento SPLM. 17 February 2025.
^ "Debridat, 7,87 mg/g, granulat do sporządzania zawiesiny doustnej. Charakterystyka Produktu Leczniczego". Rejestr Produktów Leczniczych - Rejestry e-Zdrowia. 11 July 1996. Retrieved 18 February 2025.

[1] Kaneto H, Takahashi M, Watanabe J (July 1990). "The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies". Journal of Pharmacobio-dynamics. 13 (7): 448–453. doi:10.1248/bpb1978.13.448. hdl:10069/38849. PMID 1963196.

[2] "Libertrim SII". Medicamento SPLM. 17 February 2025.

[Debridat-3] "Debridat, 7,87 mg/g, granulat do sporządzania zawiesiny doustnej. Charakterystyka Produktu Leczniczego". Rejestr Produktów Leczniczych - Rejestry e-Zdrowia. 11 July 1996. Retrieved 18 February 2025.

[1]

[2]

[3]